Dry Vapor: The Hero for the Ever-Growing CO2 Shortage

Tue, Jul 10, 2018 | By Mark W. Sawicki, Ph.D., Chief Commercial Officer, Cryoport

A carbon dioxide (CO2) shortage has been looming over the life sciences industry — yet many biopharma and biotech leaders alike have remained silent on this issue which is already shaking up our European counterparts. According to Gasworld, the European CO2 business is experiencing the worst supply situation it has seen in decades — primarily affecting Northern and Continental Europe.

With limited European access to dry ice, commonly used to maintain the temperature of life sciences specimens and products, all major suppliers of liquid CO2 will be impacted by this shortage throughout the remainder of the year. Specifically, packaging and logistics decisions will be heavily impacted as the quality of samples worldwide will be at stake.

While many continue to drink their beers and enjoy the chaos of the World Cup, they are not aware of  the desperate efforts CO2 producers are doing to in order to keep their products properly supplied. In order to avoid outrage by consumers, suppliers need to focus on prevention by finally ditching dry ice and switching over to a new, more stable source — dry vapor liquid nitrogen for shipping.

In 2016, Cryoport and KCAS Bioanalytical & Biomarker conducted a study that revealed the benefits of shipping liquid nitrogen dry vapor (LN2) Cryoport Express® shippers versus dry ice and these results exemplified numerous benefits to switching over. In fact, 30% of the biomarkers tested require cryogenic transport for consistent recovery. Additionally, there are numerous other benefits of shipping using dry vapor shippers instead of dry ice as indicated below:

dry ice vs ln2

Other results concluded that:

  • Cryoport Express® dry vapor shippers significantly reduced thermal cycling during transport when compared to dry ice shipping.
  • Sample pH was impacted in a directly proportional level to duration of shipment on dry ice.
  • Clinical efficacy, cell viability, bioanalytical and manufacturing issues encountered may in fact be logistics issues.
  • Shipping cryogenically with Cryoport Express® dry vapor shippers significantly lowered the standard deviation of the samples tested in this study when compared to dry ice shipping.
  • Cryogenic shipping is critical for the transport of cell-based reagents for manufacturing.
  • Cryogenic transportation of a cell therapy resulted in optimum viability of the cells vs. dry ice shipping.

So what’s the bottom line? This CO2 shortage is just the tip of the iceberg to a problem that shows no indication  of going away. If you wish to enjoy your beer in the future, suppliers need to make a crucial switch and ship materials safely, securely and on time with dry vapor for temperature-controlled logistics you can count on.

If you want to learn more about our trusted Cryoport Express® LN2 dry vapor shipper, get a quote and more details here.

Read our blog for the latest news on cold chain logistics issues.

Questions or comments? We welcome your feedback!

Email Us

Tags: Cold Chain, Clinical Trials Logistics, cryogenic frozen, alternative to dry ice shipping, Temperature Controlled Logistics, cryogenic shipping, cold chain shipping

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC